News and Trends 26 Feb 2018 ASIT Biotech Raises €13.9 M to Develop Allergy Immunotherapies ASIT Biotech, a Belgian company specialized in allergy immunotherapy, raised a total of €13.9M to develop immunotherapies against against grass pollen, peanut and house dust mite allergies. After raising €9.4M in January, ASIT Biotech has now brought the amount raised on the Euronext Brussels stock up to €13.9M. The funds will be put towards the Phase III […] February 26, 2018 - 3 minutesmins - By Alexander Burik Share WhatsApp Twitter Linkedin Email
News and Trends 19 Feb 2018 This Belgian Biotech Gives Us an Update on its Bulging Psoriasis Pipeline UCB has presented positive Phase IIb results for its psoriasis drug, bimekizumab, and outlined the Phase III testing of Cimzia for the condition at the American Academy of Dermatology’s annual meeting. Belgian biopharma, UCB, develops medicines for people suffering from severe diseases of the immune or central nervous systems. The company is developing a number […] February 19, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 1 Feb 2018 New Biotech Launched to Fight Cognitive Impairment Caused by Alzheimer’s Syndesi Therapeutics has been formed by UCB and a group of investors, including Novo Seeds and V-Bio to develop a group of compounds for cognitive disorders caused by diseases like Alzheimer’s. Syndesi Therapeutics will use of Belgian biotech UCB’s expertise in drug discovery for neurological conditions to develop new therapies in cognitive disorders using a new […] February 1, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 29 Jan 2018 Another One Gets Snapped Up: Ablynx has been Acquired by Sanofi for €3.9B Sanofi will acquire Ablynx and get its hands on the biotech’s exciting Nanobody technology just months after the biotech joined Europe’s billion-euro biotech club. Despite rejecting the advances of Novo Nordisk earlier this month, a decision that led to a 60% jump in Ablynx’s stock, the biotech has voted unanimously in favor of being acquired Sanofi. Sanofi has […] January 29, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
Interview 22 Jan 2018 Bravo! An Interview with the CEO of Takeda’s Recent Cell Therapy Target I sat down with Eduardo Bravo, CEO of TiGenix, to talk about the technology that made his company so attractive to the pharma giant. After beginning his career in big pharma, Eduardo Bravo took the plunge into biotech in 2005 when he saw the opportunity for a breakthrough therapy at a small Spanish biotech called […] January 22, 2018 - 6 minutesmins - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 Jan 2018 This Cytokine is Key to Autoimmune and Inflammatory Diseases An international group of researchers has found that the cytokine IL-23 is heavily involved in autoimmune and inflammatory diseases, opening the door to new therapies targeting the molecule. Research at the VIB-UGent Center for Inflammation Research has identified a crucial molecular mechanism underlying autoimmune and inflammatory diseases like psoriasis, rheumatoid arthritis, and multiple sclerosis. The study, […] January 18, 2018 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 9 Jan 2018 Biocartis and Amgen Shake Hands on Another Cancer Diagnostics Deal Biocartis will use its expertise in molecular diagnostics to produce a companion diagnostic test for Amgen’s upcoming cancer drug. Biocartis has signed its second agreement with US pharma giant, Amgen, to develop a companion diagnostic to test the suitability of a drug for a specific patient. Both deals will make use of Biocartis’ Idylla platform, a fully automated […] January 9, 2018 - 1 minutemin - By Alex Dale Share WhatsApp Twitter Linkedin Email
More News! 9 Jan 2018 Ablynx’ Stock Jumps by 60% After Rejecting Acquisition from Novo Nordisk Ablynx has rejected a generous acquisition offer from Novo Nordisk. As a result, its stock has soared and is now worth more than what Novo offered in the first place. Early this morning, Novo Nordisk has made public an offer to acquire Ablynx, a Belgian biotech that has recently joined the European billion-euro biotech club. Novo […] January 9, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 5 Jan 2018 Takeda Starts the Year Bidding for a Belgian Stem Cell Therapy Biotech Takeda has offered to acquire TiGenix subject to the upcoming European approval of its lead stem cell therapy for Crohn’s disease, Cx601. Short of two years after partnering with TiGenix for the development of a stem cell therapy, Takeda has offered to buy the remaining shares of the company in Euronext Brussels and the Nasdaq […] January 5, 2018 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
More News! 4 Jan 2018 Belgian Biotech Hits ‘Fast Forward’ on Multiple Sclerosis Therapies Rewind Therapeutics has received a boost in the development of its multiple sclerosis therapies, raising a €15.2M Series A fundraising round. Rewind Therapeutics is a young Belgian biotech, which was co-founded by CD3 and Axxam, based in Leuven, Belgium, and Milan, Italy, respectively. Today, the biotech announced that it has completed a €15.2M Series A financing […] January 4, 2018 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 19 Dec 2017 Belgian Biotech and Roche Take on Neurological and Developmental Disorders Confo Therapeutics has joined forces with Roche to develop new small molecule agonists of a G-protein coupled receptor to treat neurological and developmental disorders. Confo Therapeutics is developing a pipeline of G-protein coupled receptor (GPCR)-targeting drugs to address an unmet medical needs. The biotech spun out from the Vrije Universiteit Brussel in 2015 with the backing of […] December 19, 2017 - 2 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email
News and Trends 18 Dec 2017 Belgian Biotech’s Crohn’s Disease Cell Therapy Gets Recommended for Approval An EMA committee has supported an allogeneic stem cell therapy for the first time, as TiGenix’s Crohn’s disease candidate is backed for approval. TiGenix and its Japanese partner, Takeda, are developing a stem cell therapy for Crohn’s disease – an autoimmune disease affecting the gastrointestinal tract. This morning, the companies have revealed that their candidate, Cx601, has received the backing […] December 18, 2017 - 3 minutesmins - By Alex Dale Share WhatsApp Twitter Linkedin Email